Emergence and present status of Lu-177 in targeted radiotherapy: The Indian scenario

Radiochimica Acta

Volumn 100, Issue 2, 2012, Pages 115-126

  Banerjee, S ^a   Das, T ^a   Chakraborty, S ^a   Venkatesh, M ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

177Lu; Bone pain palliation; Production methodology; PRRT; Targeted radiotherapy

Indexed keywords

EID: 84858237853     PISSN: 00338230     EISSN: None     Source Type: Journal    
DOI: 10.1524/ract.2011.1843     Document Type: Article

References (80)

1. Volkert, W. A., Hoffman, T. J.: Therapeutic radiopharmaceuticals. Chem. Rev. 99, 2269 (1999).
2. Liu, S., Edwards, D. S.: Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconj. Chem. 12, 7 (2001).
3. Chatal, J. F., Hoefnagel, C. A.: Radionuclide therapy. Lancet 354, 931 (1999).
4. Heeg, M. J., Jurisson, S.: The role of inorganic chemistry in the development of radiometal agents for cancer therapy. Acc. Chem. Res. 32, 1053 (1999).
5. Eckelman, W. C: Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems. Eur. J. Nucl. Med. 22, 249 (1995).
6. Wilbur, D. S., Hamlin, D. K., Vessella, R. L., Stray, J. E., Buhler, K. R., Stayton, P. S., Klumb, L. A., Pathare, P. M., Weerawarna, S. A.: Antibody fragments in tumor pretargeting. Evaluation of biotinylated fab colocalization with recombinant streptavidin and avidin. Bioconj. Chem. 7, 689 (1996).
7. Srivastava, S. C., Dadachova, E.: Recent advances in radionuclide therapy. Semin. Nucl. Med. 31, 330 (2001).
8. Volkert, W. A., Goeckeler, W. F., Ehrhardt, G. J., Ketring, A. R.: Therapeutic radionuclides: production and decay property considerations. J. Nucl. Med. 32, 174 (1991).
9. Ehrhardt, G. J., Ketring, A. R., Ayers, L. M.: Reactor-produced radionuclides at the University of Missouri Research Reactor. Appl. Radiat. Isot. 49, 295 (1998).
10. 177Lu for radionuclide therapy. Appl. Radiat. Isot. 59, 109 (2003).
11. 3]octreotate. Eur. J. Nucl. Med. Mol. Img. 30, 417 (2003).
12. 177Lu-huA33: a radioimmunoconjugate against colorectal cancer. Nucl. Med. Biol. 33, 991 (2006).
13. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother. Radiopharm. 23, 202 (2008).
14. th Edn., John Wiley and Sons Inc., New York (1996).
15. Schott, M. E., Schlom, J., Siler, K., Milenic, D. E., Eggensperger, D., Colcher, D., Cheng, R., Kruper Jr, W. J., Fordyce, W., Goeckeler, W.: Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer 73, 993 (1994).
16. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin. Cancer Res. 1, 1447 (1995).
17. Meredith, R. F., Partridge, E. E., Alvarez, R. D., Khazaeli, M. B., Plott, G., Russell, C. D., Wheeler, R. H., Lo Buglio, A. F.: Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37, 1491 (1996).
18. 177Lu-EDTMP: A potential therapeutic bone agent. Nucl. Med. Commun. 19, 587 (1998).
19. Sola, G. A. R., Arguelles, M. G., Bottazzini, D. L., Furnari, J. C., Parada, I. G., Rojo, A., Ruiz, H. V: Lutetium-177-EDTMP for bone pain palliation. Preparation, biodistribution and preclinical studies. Radiochim. Acta 88, 157 (2000).
20. 177Lu. United States Patent 671, 6353 (2004).
21. 176Yb targets. Appl. Radiat. Isot. 63, 23-36 (2005). (Pubitemid 40615312)
22. 177Lu process. Appl. Radiat. Isot. 53, 421 (2000).
23. 177Lu from neutron irradiated Yb for biomedical applications. Nucl. Med. Biol. 37, 811 (2010).
24. Bakker, W. H., Kwekkeboom, D. J., De Jong, M., Konijnenberg, M. W., Janssen, P. J., Kooij, P. P., Krenning, E. P.: The presence of the long-lived contaminate lutetium-177m in lutetium-177, used for radionuclide therapy in patients. J. Nucl. Med. 44(Suppl.), 320 (2003).
25. Knapp, F. F., Mirzadeh, S., Beets, A. L., Garland, M.: Reactor production of high specific activity Lutetium-177. Eur. J. Nucl. Med. 31(Suppl. 2), S387 (2005).
26. http://www.perkinelmer.com.
27. Goeckeler, W. F., Edwards, B., Volkert, W. A., Holmes, R. A., Simon, J., Wilson, D.: Skeletal localization of samarium-153 chelates: Potential therapeutic bone agents. J. Nucl. Med. 28, 495 (1987).
28. Lewington, V. J.: Cancer therapy using bone-seeking isotopes. Phys. Med. Biol. 41, 2027 (1996).
29. Deligny, C. L., Gelsema, W. J., Tji, T. G., Huigen, Y. M., Vink, H. A.: Bone seeking radiopharmaceuticals. Nucl Med. Biol. 17, 161 (1990).
30. Silberstein, E. B.: Dosage and response in the radiopharmaceutical therapy of painful osseous metastases. J. Nucl. Med. 37, 249 (1996).
31. Cheung, A., Driedger, A. A.: Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of breast and prostate. Radiology 134, 209 (1980).
32. Robinson, R. G., Spicer, J. A., Preston, D. F., Wegst, A. V., Martin, N. L.: Treatment of metastatic bone pain with strontium-89. Nucl. Med. Biol. 14, 219 (1987).
33. Serafini, A. N.: Systematic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastases. Quart. J. Nucl. Med. 45, 91 (2001).
34. 177Lu-labeled polyaminophosphonates as potential agents for bone pain palliation. Nucl. Med. Commun. 23, 67 (2002).
35. Srivastava, S., Dadachova, E.: Recent advances in radionuclide therapy. Semin. Nucl. Med. 31, 330 (2001).
36. 117mSn (4+) diethylenetriaminepentaacetic acid for radionuclidic therapy of bone cancer. J. Nucl. Med. 41, 2043 (2000).
37. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl. Med. Biol. 14, 223 (1987).
38. 186Re complexes of tetraphosphonate ligands and their pharmacological behaviour in animal models. Nucl. Med. Biol. 28, 205 (2001).
39. 105Rh-EDTMP and its bone accumulation. Appl. Radiat. Isot. 52, 211 (2000).
40. 153Sm in rats. Appl. Radiat. Isot. 45, 949 (1994).
41. Caravan, P., Ellison, J. J., McMurry, T. J., Lauffer, R. B.: Gadolinium (III) chelates as MRI contrast agents: structure, dynamics and applications. Chem. Rev. 99, 2293 (1999).
42. 177Lu- DOTMP: A viable agent for palliative radiotherapy of painful bone metastasis. Radiochim. Acta. 96, 55 (2008).
43. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl. Radiat. Isot. 57, 174 (2002).
44. Liu, S.: Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv. Drug Deliv. Rev. 60, 1347 (2008).
45. Singh, A., Holmes, R. A., Farhangi, M., Volkert, W. A., Williams, A., Stringham, L. M., Ketring, A. R.: Human pharmacokinetics of Samarium-153-EDTMP in metastatic cancer. J. Nucl. Med. 30, 1814 (1989).
46. 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl. Radiat. Isot. 66, 1196 (2008).
47. Kwekkeboom, D. J., Mueller-Brand, J., Paganelli, G., Anthony, L. B., Pauwels, S., Kvols, L. K., O'Dorisio, T. M., Valkema, R., Bodei, L., Chinol, M., Maecke, H. R., Krenning, E. P.: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med. 46, 62S (2005).
48. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 23, 2754 (2005).
49. 3-octreotate. Eur. J. Nucl. Med. Mol. Img. 37, 212 (2010).
50. 177Lu in medium flux reactor. Appl. Radiat. Isot. 65, 301 (2007).
51. 177Lu: the Indian experience. Cancer Biother. Radiopharm. (2011), in press.
52. 177Lu-labeled hydroxyapatite particles for possible use in therapy of liver cancer. Nucl. Med. Biol. 35, 589 (2008).
53. Parkin, M. D., Bray, F., Ferlay, J., Pisani, P.: Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94, 153 (2001).
54. Cady, B.: Natural history of primary and secondary tumors of the liver. Semin. Oncl. 10, 127 (1983).
55. Nijsen, J. F. W., Van Het Schip, A. D., Hennink, W. E., Rook, D. W., Van Rijk, P. P., De Klerk, J. M. H: Advances in nuclear oncology: microspheres for internal radionuclide therapy of liver tumors. Curr. Med. Chem. 9, 73 (2002).
56. 188Re) glass microspheres. Int. J. Radiat. Oncl. Biol. Phys. 44, 189 (1999).
57. Vente, M. A. D., Hobbelink, M. G. G., Van Het Schip, A. D., Zonnenberg, B. A., Nijsen, J. F. W.: Radionuclide liver cancer therapy: from concept to current clinical status. Anti-Cancer Agents Med. Chem. 7, 441 (2007).
58. 166Ho labeled hydroxyapatite (HA) particles for radiosynovectomy. Nucl. Med. Biol. 29, 199 (2002).
59. Palma, L. D.: Diagnostic imaging and interventional therapy of hepatocellular carcinoma. Br. J. Radiol. 71, 808 (1998).
60. 188Re-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma. Nucl. Med. Commun. 25, 1007 (2004).
61. 188Re-TDD, for the treatment of liver cancer. Nucl. Med. Biol. 28, 197 (2001).
62. Leung, W. T., Lau, W. Y., Ho, S., Chan, M., Leung, N., Lin, J., Ho, K. C., Metreweli, C., Johnson, P. J., Li, A. K. C: Selective internal radiation therapy with intra-arterial iodine-131-lipiodol in inoperable hepatocellular carcinoma. J. Nucl. Med. 35, 1313 (1994).
63. Wang, S. J., Lin, W. Y., Chen, M. N., Shen, L. H., Tsai, Z. T., Ting, G.: Preparation and biodistribution of yttrium-90 lipiodol in rats following hepatic arterial injection. Eur. J. Nucl. Med. 22, 233 (1995).
64. 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study. Cancer Biother. Radiopharm. 25, 539 (2010).
65. Schneider, P., Farahati, J., Reiners, C: Radiosynovectomy in rheumatology, orthopedics, and hemophilia. J. Nucl. Med. 46, 48S (2005).
66. Chinol, M., Vallabhajosula, S., Goldsmith, S. J., Klein, M. J., Deutsch, K. F., Chinen, L. K., Brodack, J. W., Deutsch, E. A., Watson, B. A., Tofe, A. J.: Chemistry and biological behaviour of Samarium-153 and Rhenium-186-labeled hydroxyapatite particles: potential radiopharmaceuticals for radiation synovectomy. J. Nucl. Med. 34, 1536 (1993).
67. Davis, M. A., Chinol, M.: Radiopharmaceuticals for radiation synovectomy: evaluation of two yttrium-90 particulate agents. J. Nucl. Med. 30, 1047 (1989).
68. Deutsch, E., Brodack, J. W., Deutsch, K. F.: Radiation synovectomy revisited. Eur. J. Nucl. Med. 20, 1113 (1993).
69. 177Lu labeled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl. Med. Commun. 27, 661 (2006).
70. Katzenellenbogen, J. A., Carlson, K. E., Heiman, D. F., Goswami, R.: Receptor-binding radiopharmaceuticals for imaging breast tumors: Estrogen-receptor interaction and selectivity of tissue uptake of halogenated estradiol analogs. J. Nucl. Med. 21, 550 (1980).
71. 177Lu: An attempt to prepare a radiotherapeutic agent. Bioorg. Med. Chem. 13, 4315 (2005).
72. Brown, J. M.: Hypoxic cell radiosensitizers: What next? Int. J. Radiat. Oncol. Biol. Phys. 16, 987 (1989).
73. Chapman, J. D.: Hypoxic sensitizers: Implications for radiation therapy. N. Eng. J. Med. 301, 1429 (1979).
74. Zanelli, G. D., Kaelin, A. D.: Synthetic porphyrins as tumor localizing agents. Br. J. Radiol. 54, 403 (1981).
75. Fawwaz, R., Bohdiewicz, P., Lavallee, D., Wang, T., Oluwole, S., Newhouse, J., Alderson, P.: Use of metalloporphyrin in diagnostic imaging. Nucl. Med. Biol. 17, 65 (1990).
76. 177Lu labeled metronidazole for possible use in targeting tumor hypoxia. Radiochim. Acta 94, 375 (2006).
77. Shibamoto, Y., Nishimoto, S., Mi, F., Kimura, R., Sasai, K., Kagiya, V. T., Abe, M.: Evaluation of various types of new hypoxic cell sensitizers using the EMT6 single cell-spheroid-solid tumour system. Int. J. Radiat. Biol. 52, 347 (1987).
78. 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. Bioorg. Med. Chem. 12, 6077 (2004).
79. 186/188Re]-labelled porphyrin for targeted radiotherapy. Nucl. Med. Commun. 22, 1101 (2001).
80. 177Lu labeled porphyrin for possible use in targeted tumor therapy. Nucl. Med. Biol. 37, 665 (2010).